𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of parkinson's disease with the partial dopamine agonist EMD 49980

✍ Scribed by Daniele Bravi; Thomas L. Davis; M. Maral Mouradian; Dr. Thomas N. Chase

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
268 KB
Volume
8
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The motor effects of the partial dopamine agonist EMD 49980 were evaluated in parkinsonian patients under controlled conditions. EMD 49980 monotherapy resulted in a mild improvement in parkinsonian symptoms, but when co‐administered with levodopa, had no significant effect on dyskinesias or on the antiparkinsonian effect of the dopamine precursor. These results suggest that EMD 49980 exerts a net weak dopamine agonist effect but fails to ameliorate levodopa‐induced dyskinesias.

πŸ“œ SIMILAR VOLUMES

Double-blind study of pardoprunox, a new
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
✍ Juliana Bronzova; Cristina Sampaio; Robert A. Hauser; Anthony E. Lang; Olivier R πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 1 views

## Abstract This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's o